KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Payables: 2013-2024

Historic Payables for Xenon Pharmaceuticals (XENE) over the last 11 years, with Dec 2024 value amounting to $34.2 million.

  • Xenon Pharmaceuticals' Payables rose 30.14% to $36.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.3 million, marking a year-over-year increase of 26.81%. This contributed to the annual value of $34.2 million for FY2024, which is 31.75% up from last year.
  • Xenon Pharmaceuticals' Payables amounted to $34.2 million in FY2024, which was up 31.75% from $26.0 million recorded in FY2023.
  • Xenon Pharmaceuticals' 5-year Payables high stood at $34.2 million for FY2024, and its period low was $10.9 million during FY2020.
  • Moreover, its 3-year median value for Payables was $26.0 million (2023), whereas its average is $27.5 million.
  • Data for Xenon Pharmaceuticals' Payables shows a peak YoY surged of 61.95% (in 2022) over the last 5 years.
  • Over the past 5 years, Xenon Pharmaceuticals' Payables (Yearly) stood at $10.9 million in 2020, then rose by 26.14% to $13.7 million in 2021, then surged by 61.95% to $22.2 million in 2022, then grew by 16.93% to $26.0 million in 2023, then skyrocketed by 31.75% to $34.2 million in 2024.